News coverage about NuCana (NASDAQ:NCNA) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NuCana earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.3800495666015 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of NuCana (NCNA) opened at $11.28 on Thursday. NuCana has a 52 week low of $9.64 and a 52 week high of $19.95.

NCNA has been the subject of a number of recent analyst reports. Cowen initiated coverage on NuCana in a report on Monday, October 23rd. They set an “outperform” rating for the company. William Blair initiated coverage on NuCana in a report on Monday, October 23rd. They set an “outperform” rating for the company. Citigroup initiated coverage on NuCana in a report on Monday, October 23rd. They set a “buy” rating and a $23.00 price target for the company. Finally, Jefferies Group started coverage on NuCana in a report on Monday, October 23rd. They set a “buy” rating and a $25.00 price target for the company.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect NuCana (NCNA) Stock Price” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-nucana-ncna-stock-price.html.

About NuCana

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Insider Buying and Selling by Quarter for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.